Breast cancer at ESMO 2020: CDK4/6 inhibitors and checkpoint inhibitors

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancerПодробнее

Key Takeaways from ESMO: CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast CancerПодробнее

Sequencing first-line CDK4/6 inhibitors in metastatic breast cancerПодробнее

Overcoming resistance to CDK4/6 inhibitors in ER+ breast cancer via ctDNAПодробнее

CDK4/6 inhibitors for metastatic breast cancerПодробнее

ESMO 2020 Expert Video Report on CDK4 6i in the adjuvant treatment of breast cancerПодробнее

ESMO Daily Reporter Talk: The role of CDK4/6 inhibitors in the early stage of #breastcancer.Подробнее

Comment: CDK4/6 inhibitors in advanced breast cancerПодробнее

ESMO 2017: CDK4/6 inhibitors from a patient’s perspectiveПодробнее

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-posi...Подробнее

Resistance to CDK4/6 inhibitorsПодробнее

Realizing the Potential of CDK 4/6 Inhibitor Therapy in Breast Cancer: Real-World Data and EvidenceПодробнее

Highlights from ESMO 2020 in gynecological cancersПодробнее

Breast cancer at ESMO 2020: IMpassion131, SOLAR-1, PALLAS and moreПодробнее

The use of frontline CDK4/6 inhibitors + endocrine therapy in metastatic breast cancerПодробнее

ESO-ESMO-ABC guidelines in metastatic breast cancerПодробнее

CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-nega...Подробнее

CDK 4/6 Inhibitors: How are they used in metastatic breast cancer treatment?Подробнее

MONARCH 3 study: CDK4/6 inhibitors in the treatment of metastatic breast cancerПодробнее